SCHEMBL3175456

SCHEMBL3175456

Cc1nc(-c2ccc(OCCCCCOc3ccc(C(=N)NOS(C)(=O)=O)cc3)cc2)c(C(C)C)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
BRCA1 P38398 1/20 0.35
HTT P42858 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GMNN O75496 1/20 0.35
PKM P14618 1/20 0.35
THPO P40225 1/20 0.35
MTOR P42345 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175452 0.89 MEN1 (0.36) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1685013 0.89 MEN1 (0.36) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL729742 0.85 MEN1 (0.37) MEN1KMT2APRMT1F2ST14
SCHEMBL727316 0.85 MEN1 (0.37) MEN1KMT2APRMT1F2ST14
SCHEMBL729234 0.84 MEN1 (0.38) MEN1KMT2AALDH1A1PRMT1F2
SCHEMBL727965 0.83 PRMT1 (0.53) PRMT1F2ST14PLAUPLG
Hydrochloric Acid SCHEMBL3241146 0.82 PRSS1 (0.54) PRMT1F2ST14PLAUPLG
SCHEMBL727594 0.82 MEN1 (0.38) MEN1KMT2AALDH1A1PLAUPLG
SCHEMBL3192337 0.82 PRSS1 (0.52) PRMT1F2ST14PLAUPLG
SCHEMBL3469347 0.81 HDAC1 (0.45) MEN1KMT2AHRH3RARBPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242152-B2 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2012-08-14 US claimed
EP-1411935-B1 USE OF 4- (4-THIAZOLYL)PHENOXL ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM CO LTD (KR) 2010-05-19 EP claimed
US-7662840-B2 4-{5-[4-(5-Isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine (DW-1350); a leukotriene-B4 receptor antangonist; inhibiting osteoclastic bone absorption DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2010-02-16 US claimed
EP-1411935-A4 USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM IND CO LTD (KR) 2005-11-09 EP claimed
US-20040186150-A1 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis DONG WHA PHARMACEUTICAL CO., LTD. (KP) 2004-09-23 US claimed
EP-1411935-A1 USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2004-04-28 EP claimed
WO-2003007947-A1 USE OF 4-[(4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM. IND. CO., LTD. (KR) 2003-01-30 WO claimed
EP-1701722-B1 N-HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY¨]PENTOXY}BENZAMIDINE 2 METHANSULFONIC ACID SALT DONG WHA PHARM CO LTD (KR) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186150-A1 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis LTB4R, LTB4R2, CYSLTR1 MEN1 2817/4885KMT2A 1535/4885ALDH1A1 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.